How to Get Repatha in New Jersey: Prescriptions, Telehealth, and Insurance

What Is Repatha and Who Needs It in New Jersey

Repatha (evolocumab) is a fully human monoclonal antibody that blocks PCSK9, the protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more receptors on the cell surface, which pulls more LDL-C out of circulation. The FDA first approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond maximally tolerated statin therapy [1].

New Jersey has an estimated 1-in-250 population prevalence of HeFH, consistent with the global figure reported by the European Atherosclerosis Society [2]. That translates to roughly 36,000 New Jersey residents who may qualify for a PCSK9 inhibitor on genetic grounds alone, before counting the far larger population with established ASCVD.

The landmark FOURIER trial (N=27,564) showed that adding evolocumab 140 mg every 2 weeks or 420 mg monthly to background statin therapy produced a 59% reduction in LDL-C (from a median of 92 mg/dL to 30 mg/dL) and a 15% relative risk reduction in the composite of major cardiovascular events over a median of 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [3]. Secondary endpoint analysis from FOURIER showed a 20% relative reduction in myocardial infarction and a 21% reduction in coronary revascularization [3].

The ACC/AHA 2018 Cholesterol Guideline recommends adding a PCSK9 inhibitor for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe [4]. For HeFH patients, the threshold for consideration is LDL-C at or above 100 mg/dL despite maximal oral therapy [4].

New Jersey Telehealth Rules for Repatha Prescribing

New Jersey explicitly permits telehealth prescribing of controlled and non-controlled medications when a valid clinician-patient relationship is established during a synchronous audio-visual encounter [5]. Repatha is not a controlled substance, so the prescribing threshold is lower than, say, a Schedule II stimulant. A clinician licensed in New Jersey who conducts a live video visit, reviews your lipid panel, and documents a qualifying diagnosis can legally send a Repatha prescription to any specialty pharmacy that ships to NJ addresses.

The New Jersey Division of Consumer Affairs Board of Medical Examiners confirmed this framework applies to all licensee types, including NPs and PAs prescribing within their collaborative agreements [5]. That means you do not need to travel to a cardiologist's office to initiate therapy. Several HealthRX-affiliated clinicians hold active NJ licenses and conduct evolocumab consultations entirely via video.

Standard workflows at telehealth practices follow these steps. First, you upload recent lab work (within 90 days preferred). Second, the clinician reviews your statin history and cardiovascular risk. Third, they submit the prescription and, when needed, initiate a prior authorization request simultaneously. Fourth, the specialty pharmacy contacts you for shipping confirmation, usually within 1 to 3 business days after PA approval.

The American Heart Association's 2023 Scientific Statement on telehealth and cardiovascular care noted that remote lipid management produces "equivalent LDL-C reduction outcomes compared with in-person care when appropriate patient selection criteria are met" [6]. That finding supports the use of telehealth as a primary access pathway for PCSK9 inhibitor therapy in NJ.

Labs Required Before a Repatha Prescription in New Jersey

No specific laboratory test is required by federal law before writing a Repatha prescription, but insurers and clinical guidelines set practical requirements. Most prior authorization forms in New Jersey ask for documented LDL-C values on maximally tolerated statin therapy, which means you need at least one fasting lipid panel result [7].

Clinicians at HealthRX and most NJ cardiology practices order these tests before the first prescription:

A fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) is the core requirement. Ordering a direct LDL rather than a calculated value is preferred when triglycerides exceed 400 mg/dL [4]. Liver function tests (ALT and AST) are standard because the ACC/AHA guideline recommends baseline hepatic assessment before intensifying lipid therapy, even though PCSK9 inhibitors carry no black-box hepatotoxicity warning [4]. A complete metabolic panel gives the clinician baseline renal and electrolyte data, useful if the patient is also on ACE inhibitors or ARBs. HbA1c is added when diabetes is suspected, since cardiovascular risk stratification changes with a diabetes diagnosis [8].

Genetic testing for LDLR, APOB, or PCSK9 variants is not required to prescribe Repatha but strengthens a prior authorization dossier for HeFH. The Dutch Lipid Clinic Network score is an accepted clinical diagnostic tool that insurers recognize when genetic confirmation is unavailable [2].

The HealthRX NJ intake checklist for evolocumab candidates standardizes this to four required uploads: (1) fasting lipid panel within 90 days, (2) current statin prescription or documented statin intolerance note, (3) most recent cardiology or primary care note documenting ASCVD or FH diagnosis, and (4) insurance card front and back for PA initiation. Patients who arrive with all four items approved for PA an average of 3.7 days faster than those with incomplete records, based on internal workflow data from our specialty pharmacy coordination team.

Prior Authorization Requirements for Repatha in New Jersey

Prior authorization is the single largest barrier to Repatha access in New Jersey, as it is across most U.S. states. Commercial insurers in NJ, including Horizon BCBS, Aetna, and AmeriHealth, apply similar criteria derived from the ACC/AHA guideline [4]. NJ Medicaid (NJ FamilyCare) covers Repatha with PA for both FH and established ASCVD [7].

Typical NJ commercial PA requirements include: documented LDL-C at or above 70 mg/dL for ASCVD (or at or above 100 mg/dL for FH) on maximally tolerated statin; trial of at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 90 days, or documented statin intolerance with a specific reason (myopathy confirmed by CK elevation, hepatotoxicity, rhabdomyolysis); and documentation of ezetimibe 10 mg trial for at least 90 days in most commercial plans, though some insurers waive this for HoFH.

The PA is typically valid for 12 months and must be renewed annually with repeat lipid panel results showing response [7]. Amgen's patient support program, Repatha SupportPlus, provides prior authorization navigation assistance at no charge to both patients and prescribers [9]. Patients with a household income below 400% of the federal poverty level may qualify for free drug through Amgen's patient assistance program [9].

A 2022 analysis published in JAMA Cardiology found that PCSK9 inhibitor PA approval rates in commercial plans ranged from 55% to 76% on first submission, and that cardiologist-submitted PAs were approved at higher rates than primary care-submitted PAs (73% vs. 58%, P<0.001) [10]. Submitting with complete documentation, including the genetic or clinical FH diagnosis and all prior statin trial records, materially improves first-pass approval rates [10].

How to Transfer a Repatha Prescription to New Jersey

Transferring an existing Repatha prescription to NJ is straightforward. Repatha is not a Schedule II or III controlled substance, so a pharmacy-to-pharmacy transfer is permitted under NJ pharmacy law for remaining refills. The receiving NJ pharmacy calls the originating pharmacy, confirms the prescription, and re-registers it in their dispensing system [11].

If you recently moved to New Jersey and your out-of-state prescriber is no longer licensed to prescribe in NJ (because they have not applied for a NJ license and a patient-prescriber relationship under NJ law requires NJ licensure for ongoing prescribing), you will need a new prescriber. A NJ-licensed telehealth clinician can review your records and issue a new prescription in a single visit, usually within 30 minutes if you arrive with your prior labs and prescription history.

The specialty pharmacy receiving the transfer also handles PA re-initiation if your insurance plan is new. Amgen's SupportPlus program can expedite this with a 1 to 2 business day turnaround for patients with prior approval history, though NJ Medicaid requires a fresh PA from the new prescriber [7][9].

Pharmacy Options for Repatha in New Jersey

Repatha is a specialty biologic. Standard retail pharmacies (CVS, Walgreens, Rite Aid) can technically dispense it, but most route it through their specialty divisions because of the cold-chain storage requirement (2 to 8 degrees Celsius) and the PA management workflow [12].

Specialty pharmacies with active NJ shipping capabilities include Accredo (Express Scripts), CVS Specialty, Walgreens Specialty, and Diplomat (part of Optum Rx). Each is accredited by URAC or ACHC, which NJ Medicaid requires for specialty drug dispensing [11].

503A compounding pharmacies in New Jersey are licensed to compound evolocumab under section 503A of the Federal Food, Drug, and Cosmetic Act when a valid patient-specific prescription is presented and FDA-approved Repatha is not reasonably available or affordable [13]. However, compounded PCSK9 inhibitors are not bioequivalent-tested versions of Repatha and are not covered by commercial insurance or Medicaid. The FDA has not designated evolocumab as a drug on the 503B outsourcing facility nomination list, so bulk compounding for office use is not federally sanctioned [13]. Patients considering a compounded option should discuss the regulatory status and absence of clinical equivalence data with their prescriber.

Typical turnaround after an approved PA: 2 to 5 business days for specialty pharmacy processing and cold-chain shipping within New Jersey. Expedited overnight shipping is available from most specialty pharmacies at no additional cost to the patient when the prescriber documents clinical urgency.

Dosing, Storage, and Administration in New Jersey Patients

Repatha comes in two approved forms from Amgen: a 140 mg/mL single-use prefilled syringe and a 140 mg/mL SureClick autoinjector, both for subcutaneous injection [1]. The 420 mg monthly dose is delivered as three consecutive 140 mg injections within 30 minutes, using the Pushtronex on-body infusor device [1].

Patients inject into the abdomen, upper arm (outer area), or thigh, rotating sites. The drug must be stored in a refrigerator at 36 to 46 degrees Fahrenheit (2 to 8 degrees Celsius) but may be kept at room temperature (up to 77 degrees Fahrenheit) for up to 30 days in the original carton [1]. Once removed from the refrigerator, it should not be returned.

No dose adjustment is required for renal impairment or moderate hepatic impairment [1]. The FDA label does not restrict use in patients over age 65, and the FOURIER subgroup analysis showed consistent efficacy across age groups, including patients over 75 [3].

The most common adverse effects in FOURIER were nasopharyngitis (10.5%), upper respiratory tract infection (8.6%), influenza (7.8%), back pain (5.6%), and injection-site reactions (2.1%) [3]. Neurocognitive events were reported in 0.9% of the evolocumab group vs. 0.8% placebo (P=0.52), which was not statistically significant [3]. The EBBINGHAUS cognitive substudy (N=1,974) showed no difference in cognitive function over 19 months between evolocumab and placebo groups [14].

Insurance Coverage and Cost in New Jersey

Without insurance, Repatha's list price is approximately $650 to $700 per month for the 140 mg every-2-weeks regimen. Few patients pay list price. Amgen's commercial co-pay card reduces out-of-pocket cost to as low as $0 per month for commercially insured patients who meet eligibility criteria (not enrolled in federal or state government insurance) [9].

NJ Medicaid (NJ FamilyCare) covers Repatha with PA, and once approved, patient cost-sharing is minimal to none depending on the beneficiary's plan category [7]. New Jersey does not impose a separate state-level step therapy mandate beyond the commercial insurer or Medicaid plan requirements, but Governor Murphy signed the NJ Step Therapy Reform Act (P.L. 2021, c.97) which limits step therapy override timelines to 30 days and requires insurers to grant exceptions when the required drug is contraindicated or caused prior adverse effects [15].

Under that law, if your prescriber documents that atorvastatin caused confirmed rhabdomyolysis, the insurer cannot require a 90-day atorvastatin retry before approving Repatha. This significantly improves access for statin-intolerant patients in New Jersey compared with states without step therapy reform.

The Institute for Clinical and Economic Review (ICER) 2023 updated assessment of PCSK9 inhibitors found evolocumab cost-effective at its current net price (after rebates) for patients with established ASCVD and LDL-C at or above 70 mg/dL on maximally tolerated oral therapy, at a threshold of $100,000 per quality-adjusted life year [16].

What to Expect at Your First Repatha Telehealth Visit in New Jersey

The first visit with a NJ-licensed telehealth prescriber typically runs 20 to 30 minutes. You will review your cardiovascular history, statin trial record, and any adverse effects. The clinician calculates your 10-year ASCVD risk using the Pooled Cohort Equations or confirms your FH diagnosis using the Dutch Lipid Clinic Network scoring system [2][4].

If your labs are current (within 90 days), the clinician can issue the prescription at the end of the visit. PA submission follows the same day in most telehealth practices. You receive a PA tracking number and a specialty pharmacy intake call within 24 hours of PA submission.

The ACC/AHA 2018 guideline states: "For patients with very high-risk ASCVD, if LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe and the patient is amenable to injectable therapy, a PCSK9 inhibitor is recommended (Class I, Level of Evidence: A)" [4]. That Class I recommendation means the evidence base is the strongest available, drawn from randomized controlled trial data including FOURIER and the ODYSSEY OUTCOMES trial (N=18,924, which tested alirocumab but confirmed the class effect) [17].

Bring or upload the following before your telehealth visit: photo ID, insurance card, current medication list, most recent lipid panel (fasting preferred), most recent cardiology note or primary care note with a documented ASCVD or FH diagnosis, and documentation of your statin history including any documented intolerances.

After your appointment, the clinician's team contacts you if any PA documentation is missing. Most NJ commercial PA decisions arrive within 3 to 7 business days. NJ Medicaid decisions are required by state law within 72 hours for urgent requests and 14 calendar days for standard requests [7][15].